1. Characteristics of SARS-CoV-2 and potential pharmacological treatment
- Author
-
Pawlik L, Śpiołek E, Fichna J, and Tarasiuk A
- Subjects
- COVID-19, China epidemiology, Coronavirus Infections diagnosis, Coronavirus Infections epidemiology, Humans, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral epidemiology, Severe acute respiratory syndrome-related coronavirus, SARS-CoV-2, Betacoronavirus growth & development, Betacoronavirus isolation & purification, Betacoronavirus pathogenicity, Coronavirus Infections drug therapy, Coronavirus Infections virology, Pneumonia, Viral drug therapy, Pneumonia, Viral virology
- Abstract
In December 2019 in Wuhan, China the first cases of previously unknown, coronaviral infection-induced pneumonia have been reported. The new virus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) was named after SARS-CoV due to their similarities and the disease caused by the pathogen is COVID-19 (Coronavirus Disease 2019). On 11 March 2020 WHO (World Health Organization) defined the rapidly increasing number of incidents of COVID-19 as a pandemic. In this review we will present recent information about the SARS-CoV-2 focusing on the origin, clinical picture, diagnostic methods, structure, replication cycle of SARS-CoV-2 and potential pharmaceutical measures against COVID-19.
- Published
- 2020
- Full Text
- View/download PDF